Savic, Aleksandar (19537112200)Aleksandar (19537112200)SavicMarisavljevic, Dragomir (55945359700)Dragomir (55945359700)MarisavljevicKvrgic, Vanja (54782884200)Vanja (54782884200)KvrgicStanisavljevic, Natasa (36163559700)Natasa (36163559700)Stanisavljevic2025-06-122025-06-122014https://doi.org/10.1159/000354840https://www.scopus.com/inward/record.uri?eid=2-s2.0-84901348957&doi=10.1159%2f000354840&partnerID=40&md5=32b7b7ed8abcecfb0ef579af52f38a07https://remedy.med.bg.ac.rs/handle/123456789/8758The objective of this study is to externally validate the recently published Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndrome (MDS) and compare it with the International Prognostic Scoring System (IPSS). We conducted a retrospective study of 173 adult MDS patients who had not received disease-altering treatment. Using the Cox hazard method, we found the IPSS-R to be a significant predictor of survival (p < 0.001, hazard ratio, HR = 1.82, 95% confidence interval, CI 1.57-2.12) and time to acute myeloid leukemia (AML; p < 0.001, HR = 2.05, 95% CI 1.55-2.70). The IPSS-R has greater prognostic power for survival and time to AML compared with the IPSS, given higher Somers' D values (0.41 vs. 0.39 and 0.55 vs. 0.53, respectively). Using the log-rank test, we found a significant difference when comparing IPSS-R groups (p < 0.02), with the exception of the high-risk versus very high-risk group comparison. The IPSS-R reclassified low-risk and intermediate-1 IPSS groups into four groups (log-rank, p < 0.001) and intermediate-2 and high-risk IPSS groups into three groups (log-rank, p < 0.04, excluding high-risk vs. very high-risk comparison). We conclude that the IPSS-R has significant prognostic utility for MDS patients. © 2013 S. Karger AG, Basel.Myelodysplastic syndromePrognosisRevised International Prognostic Scoring SystemSurvival